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Background: The purpose of this study was to evaluate the results of hepatectomy with inferior vena cava or
hepatic vein resection, followed by vessel reconstruction with an artificial vascular graft.
Methods: From 2000 to 2011, 1,434 patients underwent several types of hepatectomy at our institution. Of these,
we reviewed the cases of eight patients (0.56%) who underwent hepatectomy with inferior vena cava or hepatic
vein resection and subsequent reconstruction using an expanded polytetrafluoroethylene (PTFE) graft.
Results: We resected the inferior vena cava in six patients and the hepatic vein in two patients. All eight patients
underwent subsequent reconstruction using an expanded PTFE graft. The median operative time was 443 minutes and
the median blood loss was 2,017 mL. The median postoperative hospital stay period was 18.5 days and the in-hospital
mortality rate was 0%. Complications occurred in four patients: two patients experienced bile leakage, one experienced a
wound infection, and one experienced pleural effusion. The two patients who experienced bile leakage had undergone
reoperation on postoperative day 1. No complication with the artificial vascular graft occurred in these eight cases.
Histological invasion to the replaced inferior vena cava or hepatic vein was confirmed in four cases. All artificial vascular
grafts remained patent during the observation period.
Conclusions: Hepatectomy combined with inferior vena cava or hepatic vein resection, followed by reconstruction with
an expanded PTFE graft can be performed safely in selected patients.
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Liver resection is often the only valid treatment for patients
with hepatic tumors such as hepatocellular carcinomas,
cholangiocarcinomas and metastatic hepatic carcinomas.
Whether hepatectomy can be performed often influences
the prognosis of these patients. If the liver tumor is other-
wise unresectable, liver surgery requiring venous resection
and reconstruction may be the only chance for a cure. Liver
tumors invading the inferior vena cava (IVC) or hepatic
vein (HV) roots were previously a contraindication for hep-
atectomy because of the high surgical risk, but along with
the progress in liver transplantation, complex hepatecto-
mies, such as those with vein reconstruction, have also be-
come relatively safe [1]. When a liver tumor invades the* Correspondence: kaorioritatsu@ybb.ne.jp
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unless otherwise stated.IVC or HV, a liver resection combined with simple closure
or patch reconstruction of the IVC or HV is performed
when the range of infiltration is small. However, when the
range of the infiltration is large, a graft is required. HV re-
construction is also occasionally required to reduce the re-
sidual liver congestion area and ensure an effective residual
liver volume. However, in terms of liver surgery using an
artificial vascular graft, there are few reports and many un-
certainties about the results, prognosis and graft patency.
In this study, we reviewed the cases of eight patients
who underwent hepatectomy with IVC or HV resection
and subsequent reconstruction using an expanded poly-
tetrafluoroethylene (ePTFE) graft between 2000 and
2011. The results validate the use of the artificial vascu-
lar graft in liver surgery.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 Preoperative enhanced computed tomography and reconstructed three-dimensional computed tomography. (A) Intrahepatic
cholangiocarcinoma: tumor invasion of the inferior vena cava was suspected (patient 2). (B) Hepatocellular carcinoma: tumor invasion of the vein
(V3) was suspected (patient 4). (C) Hepatocellular carcinoma: the left hepatic vein diverged to confluent V2 and V3 near the root and V3 was
compressed by the tumor over a 3 cm length (patient 4). IVC, inferior vena cava; MHV, middle hepatic vein.
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Patients
From 2000 to 2011, 1,434 patients underwent several types
of hepatectomy at the Department of Gastroenterological
Surgery I, Hokkaido University Hospital. Eight of these pa-
tients (0.56%) underwent hepatectomy with IVC or HV re-
section and subsequent reconstruction using an ePTFE
graft (Gore-Tex, WL Gore & Associates, Inc., USA). Six of
these patients needed IVC resection and two needed HV
resection. The clinical and surgical features of the patients
are listed in Table 1. There were six men and two women;
their ages ranged from 50 to 84 years with a median age of
64.5 years. Three of the liver tumors were intrahepatic cho-
langiocarcinomas, two were hepatocellular carcinomas, and
the remainder were single cases of metastatic tumor from
colon cancer, metastatic tumor from gastrointestinal stro-
mal tumor, and sarcomatoid mesothelioma. Patient 3 had a
recurrent gastrointestinal stromal tumor in the residualFigure 2 Hepatectomy combined with inferior vena cava or hepatic v
vascular graft. (A) Left hepatectomy with reconstruction of the inferior ve
WL Gore&Associates, Inc., USA) graft (patient 2). (B) Right trisectionectomy
(patient 4). CBD, common bile duct; IVC, inferior vena cava; RHA, right hepaliver (S4); this patient underwent a fourth hepatectomy,
after a right hepatectomy and two partial resections of the
liver. The other patients were primary surgical cases. The
preoperative diagnosis of patient 5 was retroperitoneal leio-
myosarcoma, but the postoperative histological diagnosis
was sarcomatoid mesothelioma. Biliary reconstruction by
Roux-en-Y hepaticojejunostomy was performed in a single
case (patient 1). Informed consent was obtained from each
patient in accordance with the Ethics Committee Guide-
lines at our institution.
Preoperative management
Preoperative management was done according to our previ-
ous report [2]. All patients were evaluated by abdominal
and chest computed tomography (CT) to assess the pri-
mary tumor, vascular structures and distant metastases. In
addition, we reconstructed three-dimensional (3D) images
using multidetector row-CT to understand the positionalein resection followed by reconstruction with an artificial
na cava using an expanded polytetrafluoroethylene (ePTFE, Gore-Tex,
with reconstruction of the left hepatic vein using an ePTFE graft
tic artery; RHV, right hepatic vein; RPV, right portal vein.
Orimo et al. World Journal of Surgical Oncology 2014, 12:113 Page 4 of 8
http://www.wjso.com/content/12/1/113relationships between the tumor and vessels in greater de-
tail (Figure 1). The volumes of the liver parenchyma and tu-
mors were measured using a 3D workstation and the
effective resection ratio (%) was calculated. The indocya-
nine green retention rate at 15 min (ICGR15) was
measured to evaluate the liver functional reserve. An algo-
rithm (Hokkaido University Algorithm) incorporating the
ICGR15 and remnant liver volume was used to determine
the operative procedure, as previously described [2].
Surgical methods
The surgical method used for the liver resections has been
previously described [2]. Transection of the liver paren-
chyma was performed using the hook spatula of an ultra-
sonic harmonic scalpel (Ethicon EndoSurgery, San Angelo,
Texas, USA) and either a DS3.0 Dissecting Sealer (Medtro-
nic) or bipolar cautery with a saline irrigation system. In-
flow occlusion was applied in an intermittent manner, with
15 min of occlusion alternated with 5 min of reperfusion.
During transection of the liver parenchyma, the central
venous pressure was maintained below 5 cm H2O to pre-
vent venous hemorrhage. Liver resection in this study in-
cluded two right trisectionectomies, two left hepatectomies,
one right hepatectomy, and three partial resections.
Starting with Kocher’s maneuver, the IVC was sepa-
rated from the retroperitoneum and secured above the
level of the right renal vein. After mobilizing the right
and left liver lobes, the right and left sidewalls of the
IVC were exposed, and the IVC was separated from the
retroperitoneum and secured above the level of the HV
roots. When IVC resection was necessary because of
tumor invasion and a wall resection of the IVC involved
less than a quarter of the entire circumference, the IVC
was reconstructed by primary repair. When the wall re-
section of the IVC involved less than one-half of the en-
tire circumference, the IVC was reconstructed with an
umbilical vein patch graft or an ePTFE patch graft
(n = 1). When the defect of the IVC wall was greater
than one-half of the entire circumference, the IVC was
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IVC, inferior vena cava; LHV, left hepatic vein; HV, hepatic vein.(n = 5; Figure 2). When HV resection and reconstruction
was necessary because the tumor invaded the HV and
the planned residual liver volume was expected to be
smaller than 40% of the whole liver, the HV was recon-
structed with a 10 mm ringed ePTFE tube graft (n = 2;
Figure 2). Resection and reconstruction of the IVC or
HV were performed after transection of the liver
parenchyma.
In reconstructing the IVC with an ePTFE graft, the
IVC was clamped at both the suprahepatic and supra-
renal portions. All the IVC segments replaced in these
cases were retrohepatic IVC segments. During HV re-
construction, the ePTFE graft was bypassed either from
V3 to the IVC (patient 4) or from the middle hepatic
vein (MHV) to the IVC (patient 6). In reconstructing
the IVC with an ePTFE graft, the IVC was clamped as
follows: the IVC was clamped at both the suprarenal and
suprahepatic regions, the liver and invaded IVC was re-
moved, and the IVC was reconstructed with an ePTFE
graft. After reconstruction, the IVC clamp was first re-
leased at the suprarenal region and later at the suprahe-
patic region for the air flush. In reconstructing the HV
with an ePTFE graft, the IVC was clamped as follows:
the IVC was clamped at both the suprarenal and supra-
hepatic regions and inflow occlusion was applied, and
the HV was reconstructed with an ePTFE graft. After
HV was reconstructed and inflow occlusion was re-
leased, the IVC clamp was first released at the supra-
renal region and later at the suprahepatic region for the
air flush. At our institution, venovenous bypass is used
in case of a decrease in systolic blood pressure of less
than 60 mmHg by test clamping the IVC even after vol-
ume loading. A venovenous bypass was not used for any
the patients in this study because no cases had a de-
crease in blood pressure when clamping the IVC, al-
though we were prepared to use the bypass.
Postoperative management
No anticoagulant therapy was used for patients undergo-
ing reconstruction of the IVC with an ePTFE graft.tency Outcome Histological invasion to the
replaced IVC or HV
y, 6mo) Disease death (7y, 1mo) Positive
y, 3mo) Disease death (1y, 3mo) Negative
y, 9mo) Alive (9y, 9mo) Negative
y, 5mo) Disease death (2y) Negative
mo) Disease death (8mo) Positive
mo) Disease death (9mo) Negative
y, 7mo) Alive (2y) Positive
0mo) Alive (2y, 7mo) Positive
Figure 3 Histological invasion to the replaced inferior vena
cava by the tumor was confirmed (patient 8). (A) Gross
appearance (B) Low magnification. (C) High magnification.
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tain an international normalized ratio of 1.5 to 2.0 for
patients undergoing reconstruction of the HV with an
ePTFE graft. Ultrasound sonography was performed
daily for one week after surgery to check the graft pa-
tency. CT was performed on postoperative day 7 to
evaluate the graft patency, and follow-up studies after
discharge were conducted one month after the operation
and at three-month intervals thereafter.
Results
The details of the surgical results are listed in Table 2.
We resected the IVC in six patients and the HV in two.
All eight patients underwent subsequent reconstruction
using an ePTFE graft. The median operative time was
443 minutes and the median blood loss was 2,017 mL.
Other combined resected organs were the bile duct in
one case and the diaphragm and right lung in another.
Complications occurred in four patients: two patients
experienced bile leakage, one experienced a wound in-
fection, and one experienced pleural effusion. Patients 2
and 8 underwent reoperations to treat bile leakage on
postoperative day 1. The median postoperative hospital
stay period was 18.5 days and the in-hospital mortality
rate was 0%. No complications with regard to the artifi-
cial vascular graft occurred in these patients. Histological
invasion of the replaced IVC or HV was confirmed in
four cases (patients 1, 5, 7 and 8; Figure 3). The median
duration of follow up was 24 (range, 8 to 117) months.
After surgery, CT or magnetic resonance imaging was
performed at one- to three-month intervals to determine
recurrence and check the graft patency. When the graft
patency period was defined as the period from the oper-
ation to the last evidence of radiological patency, all artifi-
cial vascular grafts remained patent during the observation
period (Figure 4).
Discussion
We examined the cases of eight patients who underwent
liver surgery combined with IVC or HV resection, followed
by vessel reconstruction with artificial vascular grafts, and
explored the validity of the use of ePTFE grafts in liver sur-
gery. There were no surgical complications accompanying
the use of artificial vascular grafts and all grafts in patients
were patent. Therefore, liver resection combined with vessel
reconstruction of the IVC or HV with subsequent recon-
struction using ePTFE grafts can be performed safely in se-
lected patients. Furthermore, our series contained two
cases of over five-year survival (Table 2), although the un-
treated option for hepatic malignancy offers only a median
survival of about three months [3] and chemotherapy does
not offer a cure. Therefore, liver tumors invading the IVC
or HV roots are not necessarily a contraindication for
hepatectomy.In liver surgery, there are a few cases that can only be
cured by performing resection and reconstruction of the
IVC or HV. Primary closure is impossible, and patch clos-
ure is often difficult during IVC reconstructions when the
tumor invasion range is large; thus, reconstruction with an
artificial vascular graft is often required [4]. Experience of
living donor liver transplantation has shown that HV re-
construction using a vascular graft is sometimes necessary
to reduce the residual liver congestion area and ensure ef-
fective liver volume [5]. Many graft materials can be used,
including cryopreserved veins [6], the external iliac vein [7],
Figure 4 Postoperative enhanced computed tomography. (A) The patency of an inferior vena cava graft has been kept for nine years after
the operation (patient 3). (B) The patency of a hepatic vein graft has been kept for one year after the operation (patient 4).
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ficial vascular graft [10]. Autologous or cryopreserved veins
work well in these grafts, if available, but they are often un-
available because there is a limit to the size and distance.
Furthermore, surgical procedures for using these veins are
often complex and time consuming. The artificial vascular
graft has the advantages of freedom of length and diameter
and can be used to respond to various situations. However,
use of an artificial vascular graft has the potential risk of in-
fection and thrombosis. Therefore, we evaluated our experi-
ence of using artificial vascular grafts in liver surgery.
In the cases presented here, complications occurred in
four patients: two patients experienced bile leakage, one
experienced a wound infection, and one experienced
pleural effusion. However, there were no complications
involving the ePTFE grafts. Graft infection is the most
serious complication related to the use of ePTFE grafts.
In our series, biliary reconstruction by Roux-en-Y hepa-
ticojejunostomy was performed in one case and reopera-
tions were performed for bile leakage on postoperative
day 1 in two cases, but graft infection did not occurred
in any of the patients. Arii et al. [4] reported 11 cases of
hepatectomy with IVC resection, followed by IVC recon-
struction with an ePTFE graft, with no graft infections.
Azoulay et al. [11] reported 22 cases of hepatectomy
with IVC resection and reconstruction, of which 10
cases were reconstructed with an ePTFE graft. They also
reported no graft infections. Hemming et al. [12] re-
ported 22 cases of hepatectomy with IVC resection and
reconstruction, of which 16 cases were reconstructed
with an ePTFE tube graft or an ePTFE patch (including
five biliary reconstruction cases and two postoperative
bile leak cases); graft infection did not occur in any of
these cases, as with our study. These reports only de-
scribe IVC reconstruction, but we have also performed
HV reconstructions with an ePTFE graft in liver resec-
tion in this report. Using an ePTFE graft in living donor
liver transplantation has also been reported, and there
has been no evidence of clinical infectious complications
derived from the use of ePTFE grafts [13]. As seen inthe cases reported here, the ePTFE graft can be used
without serious infectious complications in most cases.
The ePTFE graft is considered to have strong resistance
to infection compared with other artificial vascular
grafts, such as Dacron grafts [14,15]. However, there
have been reports that ePTFE may be susceptible to in-
fection [16]. One graft infection case that occurred dur-
ing multiple organ failure resulting from a postoperative
duodenal perforation has been reported [17]. Therefore,
the use of ePTFE graft in the case of a contaminated op-
eration must be considered carefully. In our series, two
cases with postoperative bile leakage were treated one
day after surgery. This prompt treatment may be import-
ant for the prevention of graft infection.
Another important issue with ePTFE grafts is graft pa-
tency. In our series, all the cases showed graft patency
throughout the observation periods. In liver surgery
using an ePTFE graft for IVC reconstruction, the ePTFE
graft has been reported to show very high patency rates
[4,11,12,18], which is consistent with our results. Re-
cently, Matsuda et al. [19] reported combined resection
of the IVC with replacement by an ePTFE graft in a liv-
ing donor liver transplantation for hepatocellular carcin-
oma beyond the Milan criteria. They observed no
complication related to the ePTFE graft. The ePTFE
graft is considered to resist respiratory compression and
graft collapse [18], resulting in few cases of graft throm-
bosis development. Another advantage of the ePTFE
graft for IVC reconstruction is that it generally prevents
narrowing of the lumen that could occur by compres-
sion of the graft during liver regeneration [15]. There-
fore, many authors prefer to use the ePTFE graft for
IVC reconstruction, rather than other graft materials.
Good graft patency has also been reported when using
an ePTFE graft for HV reconstruction combined with
liver resection [10]. Use of the ePTFE graft for MHV re-
construction in living donor liver transplantation has
also been reported [13]. In this report, the early patency
rate of the ePTFE graft was good, whereas the late pa-
tency rate was reduced. However, the late obstructions
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impact on postoperative liver congestion, liver regener-
ation, or patient survival. With respect to the duration
of graft patency, one to two weeks is considered to be
enough to maintain adequate liver graft function because
intrahepatic venous collateral can be expected to de-
velop within one week of the operation [20]. Another re-
port has described the conversion of the portal tract to
an outflow channel within one hour, and intrahepatic
venous collateral formation within two weeks when the
hepatic vein was occluded [21]. Luminal thrombus for-
mation is uncommon when an ePTFE graft is used for
IVC reconstruction because the IVC can be classified as
a high-flow vessel. By contrast, the MHV may be a low-
flow vessel, resulting in the possibility of luminal
thrombus formation [22]. Although a short period of
graft patency may be acceptable in a case of HV recon-
struction, warfarin should be used for long patency for
cases of chronic hepatitis and liver cirrhosis, in order to
secure liver volume. We did not stop warfarin because
there are no established guidelines for the appropriate
duration of the anticoagulant therapy.
The important feature of liver resection using an artifi-
cial vascular graft is to secure tumor-free margins for
patients in whom tumor-free margins cannot be ob-
tained with standard liver resection. Recently, Hemming
et al. [23] reported that the only possible method for
obtaining tumor-free margins would be the use of
ex vivo resection techniques if there was complex in-
volvement of the IVC, hepatic veins, and/or portal struc-
tures. Ex vivo resection is rarely needed because most
tumors can be resected with less technically demanding
techniques; however, ex vivo resection may be effective
for patients in whom obtaining tumor-free margins dur-
ing an in situ aggressive surgical procedure is not
possible.
Hepatocellular carcinomas often expand with a capsule
and form a tumor thrombus into intrahepatic vessels
rather than directly invading the vessels. By contrast,
adenocarcinomas, such as cholangiocarcinomas and meta-
static tumors from colon cancer, tend to invade surround-
ing organs directly [24]. Because various situations can
lead to a case of liver surgery requiring vascular resection,
accurate preoperative assessment is essential. Recently,
3D-CT was reported to be useful for evaluating the
positions of liver tumors and vessels precisely. It yields
an accurate preoperative assessment and is a useful aid
for surgical planning [25-27]. We also take advantage of
3D-CT in preoperative simulations to avoid unneces-
sary vascular resections or to prepare a vascular graft
before surgery. With respect to the IVC invasion, histo-
logical invasion of the replaced IVC was confirmed in
four cases in our series, and the accuracy rate for pre-
operative diagnosis of IVC invasion was 66.7% (four outof six). Although 3D-CT is generally considered to be
useful for preoperative simulation [25], novel diagnostic
procedures for vascular invasion are expected.
Conclusions
Our results indicate liver resection combined with IVC
or HV vessel reconstruction using an ePTFE graft can be
performed relatively safely in selected patients. Further-
more, precise preoperative assessment and surgical plan-
ning are mandatory to safely perform liver surgeries
requiring venous reconstruction.
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